170856-29-8

Basic information

• Product Name: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate
• Synonyms: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate
• CAS NO: 170856-29-8
• Molecular Weight: 295.335
• Mol File: 170856-29-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(170856-29-8)
• EPA Substance Registry System: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(170856-29-8)

Safety Data

• Hazardous Substances Data: 170856-29-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 591-27-5 m-Hydroxyaniline 
• 19962-06-2 tert-butyl 3-hydroxyphenylcarbamate 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1310744-77-4 (R)-2-(3-(((3-(carboxymethoxy)phenyl)amino)methyl)benzamido)pentanedioic acid 
• 170855-82-0 1,5-Bis-(cyclopropylcarbonylmethyl)-3-(N'-(m-(carboethoxymethoxy)phenyl)ureido)-1H-1,5-benzodiazepine-2,4(3H,5H)-dione 
• 58559-52-7 3-aminophenoxyacetic acid ethyl ester 

Relevant articles and documents

KIF18A INHIBITORS

Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.

Benzodiazepine derivative

A benzodiazepine derivative of the formula (I): STR1 wherein R 1 is a bond, --CH 2 --, --CH 2 O--, --SCH 2 -- or a group of the formula: STR2 R 2 is a lower alkyl, --COOR 5, --CONH(CH 2) n COOR 5, --CONHSO 2 R 5, --SO 2 NHCOR 5, or an optionally substituted heterocyclic group (R 5 is a hydrogen atom, lower alkyl or benzyl and n is an integer of 1 to 5); R 3 is a bond, --CO-- or --CONH--; and R 4 is an optionally substituted heterocyclic group, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, optionally substituted aryl, or lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, which has a high affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors, and is useful for treating diseases associated with gastrin receptors and/or CCK-B receptors without inducing the side effects associated with CCK-A receptors.

Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry

A series of CCK-B/gastrin receptor antagonists, 2,4-dioxo-1,5-benzodiazepine derivatives with a plane of symmetry, were designed, synthesized, and evaluated for antagonistic activity. Structure-activity relationship studies revealed that carbonylmethyl groups at both N-1 and N-5 positions and hydrophilic groups, such as the carboxyl group on the benzene ring attached to the ureido group at the C-3 position, brought about potent affinity and subtype selectivity for CCK-B/gastrin receptors. Several compounds showed excellent in vivo inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats.